Ann: FDA Grants Orphan Drug Designation for Revascor, page-138

If you look at my comments there I am much harsher towards MEM management than I am towards MSB management.

I thought I did my DD, and I learned a valuable expensive lesson there. Though TBH it was a very minor investment, something I wasn't upset to lose.

Wouldn't have minded someone coming around there warning me about management. If you do look tho, many holders are very critical of what has been done, and very skeptical over the recent releases.

So that's a big difference to what is seen here.

The only reason I come around here a bit smug is because of the hostility I have experience in the past, when I tried warning people about the issues around the data that I saw (when it was $5). Someone attempted to doxx me where I worked!

So yeah, do what you want, listen to who you want, don't worry about dd, whatever. Or feel free to ignore me.